New antibody selectively targets immune cells that suppress anti-tumor responses
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME”
2025-07-16
(Press-News.org)
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME.”
BUFFALO, NY – July 16, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.”
In this study, researchers from the National Institute of Allergy and Infectious Diseases, led by first author Maja Buszko and corresponding author Ethan M. Shevach, discovered a new monoclonal antibody that selectively targets a subset of immune cells called regulatory T cells (Tregs). These cells, while normally important for preventing autoimmunity, also can block the body’s ability to fight cancer by suppressing anti-tumor immune responses. This discovery could lead to novel cancer therapies that strengthen the immune system’s capacity to attack tumors.
The researchers identified an anti-CD25 monoclonal antibody with several atypical properties and named it 2B010. To evaluate its effects, they used humanized mice, laboratory mice that are engineered to carry human immune cells, to closely mimic how human immune systems respond to cancer. The treatment of these mouse models with 2B010 significantly decreased the number of Tregs in tumors and boosted the activity of CD8+ T cells, which are essential for killing cancer cells. Importantly, 2B010 worked without disrupting other key immune functions. Unlike traditional Anti-CD25 antibodies, it did not interfere with interleukin-2 (IL-2) signaling, which is essential for the growth and activity of effector T cells that fight cancer.
“2B010 also had no effect on IL-2 induced STAT5 phosphorylation or CD4+ T cell proliferation in vitro while both were blocked by Clone D1 further supporting the view that 2B010 does not recognize the IL-2 binding site.”
This finding is especially significant because high levels of Tregs in tumors are associated with poor outcomes in many cancers. By specifically removing these cells, 2B010 may help overcome one of the main barriers to current immunotherapy approaches. Its ability to preserve IL-2 signaling could also make it safer and more effective when used alone or in combination with existing therapies such as immune checkpoint inhibitors.
While the 2B010 antibody showed strong effects in reducing Tregs and boosting immune cell activity, the study did not observe changes in tumor size in these models. Researchers suggest this may be due to limitations in the preclinical systems used, such as the lack of tumor-specific T cells in humanized mice. Nevertheless, these findings demonstrate that 2B010 has a unique mechanism of action that could complement other cancer immunotherapies in future clinical trials.
In conclusion, the development of 2B010 is a promising step toward selectively disrupting the immune suppressive environment in tumors. As researchers continue to refine and test this antibody, it could become a powerful tool for enhancing the effectiveness of cancer treatments and improving outcomes for patients.
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28752
Correspondence to: Ethan M. Shevach – eshevach@Niaid.NIH.gov
Keywords: cancer, Treg, CD25, TME, mAb, GVHD
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-07-16
Researchers have developed a powerful new tool that makes it easier to study the mix of cell types in human tissue, which is crucial for understanding diseases such as cancer.
Developed by researchers at Oregon Health & Science University’s Knight Cancer Institute, the tool, dubbed OmicsTweezer, uses advanced machine learning techniques to analyze biological data at a scale large enough to estimate the composition of cell types in a sample of tissue that may be taken from a biopsy. This process allows scientists to map the cellular makeup of tumors and surrounding tissues — an area ...
2025-07-16
The 2025 World Cultural Council’s award winner is announced
The winner of the 2025 “Albert Einstein” World Award of Science is Professor Mercouri G. Kanatzidis, Charles E. and Emma H. Morrison Professor in the Department of Chemistry and the Department of Materials Science and Engineering at Northwestern University, USA. He is also a Senior Scientist at Argonne National Laboratory.
Professor Kanatzidis is recognized for his groundbreaking contributions as a pioneer in shaping the field solar photovoltaic materials through his seminal work on halide perovskite semiconductors. He has made fundamental contributions for creating materials enabling ...
2025-07-16
The significant philanthropic support comes at a time of uncertainty for federal research funding
The grants will support new approaches to the deadliest cancer, from novel early detection methods, using AI to identify those with higher risk, and new immunotherapy treatments
LOS ANGELES, July 16, 2025 — The Stephenson Global Pancreatic Cancer Research Institute and its partner City of Hope, one of the country’s largest and most advanced cancer research and treatment organizations, today announced the six inaugural recipients of the prestigious Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, ...
2025-07-16
Tampa, FL, USA - The Global Virus Network (GVN), a coalition of leading human and animal virologists from 80+ Centers of Excellence and Affiliates in more than 40 countries, is sounding the alarm over a sharp resurgence of measles cases in the United States and globally. This resurgence, fueled by falling vaccination rates, threatens to erode decades of public health progress.
Measles is one of the most contagious viruses known to humans and is entirely preventable through routine vaccination. The U.S. is now experiencing its highest ...
2025-07-16
Reviving floodplain wetlands slashes carbon emissions by 39% and restores critical ecosystem functions in one year – without the methane spike typically seen in restored peatlands, a new study has found.
Peatlands are known as top carbon sinks, but can produce up to 530% more methane after restoration, potentially offsetting short-term climate benefits.
Whereas floodplain, or riparian wetlands, which comprise over half of global wetlands, are often overlooked due to their lower carbon storage.
Now a new study in the Journal of Environmental ...
2025-07-16
In a field where collaboration is key to progress, Jack Berkery, a leader in U.S. fusion research, is heading to Japan as a Fulbright Specialist to help strengthen the ties that power the future of fusion energy. Berkery is the deputy director of the National Spherical Torus Experiment-Upgrade (NSTX-U) at the U.S. Department of Energy’s Princeton Plasma Physics Laboratory (PPPL). The Fulbright Specialist Program pairs specialists with select host institutions to build international partnerships.
Berkery’s two-week visit to Japan will include meetings with researchers at Kyushu University and participation ...
2025-07-16
GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S. adults (ages 18 to 91) led by the Kinsey Institute at Indiana University with DatingNews.com, GLP-1 users reported a wide range of physical, social, and psychological shifts they attributed to the drug.
Among respondents, 8% reported having used a GLP-1 medication to assist with weight loss, with no significant difference difference in use between men and women. Among GLP-1 users, 59% reported at least one impact of the drug on their dating life including:
17% ...
2025-07-16
DALLAS, July 16, 2025 — The American Heart Association, the world’s leading nonprofit organization focused on heart and brain health for all, announces the appointment of two leading health and science leaders, Jennifer Ashton, M.D., M.S. and Joseph Woo, M.D., FAHA, to its volunteer Board of Directors, effective July 1, 2025.
Dr. Ashton and Dr. Woo bring clinical leadership, health media influence and scientific innovation to the Association as it enters its second century, intensifying its efforts to change ...
2025-07-16
Japan’s green transformation (GX) strategy aims to achieve carbon neutrality by 2050 through growth-oriented carbon pricing, but some parties face litigations against renewable energy projects. A recent study analyzed Japan’s GX Promotion Act and compared it to the United States’ clean energy policies, including both successes and setbacks. The findings stress that early stakeholder involvement and cooperation with local communities are essential for successful renewable energy projects and a seamless green transition.
As nations worldwide race to ...
2025-07-16
Drawing inspiration from the veinous ears of jackrabbits and elephants, Drexel University researchers have come up with a new approach to passive heating and cooling that could one day make buildings more energy efficient. Their concept, recently published in the Journal of Building Engineering, embeds a vascular network within cement-based building materials that, when filled with paraffin-based material, can help passively regulate the surface temperature of walls, floors and ceilings.
The approach is an effort to address the substantial contribution of building energy demand — nearly 40% of all energy use — to the production of greenhouse gas. ...
LAST 30 PRESS RELEASES:
[Press-News.org] New antibody selectively targets immune cells that suppress anti-tumor responses
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME”
